Abstract data from the BRUIN CLL-322 trial reveals that adding pirtobrutinib to a venetoclax-rituximab backbone provides a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for patients with previously treated CLL, without a substantial increase in toxicity.
An expert expresses a strong preference for time-limited CLL therapies over continuous maintenance treatments. The rationale is that getting patients into a deep remission and then off treatment entirely leads to a better overall experience and quality of life, even if they eventually relapse.
For high-risk CLL patients who progress after both covalent BTK inhibitors and venetoclax, pirtobrutinib is not just the next line of therapy. It is strategically used to achieve disease control, creating a window to prepare the patient for a more definitive and potentially curative CAR-T cell therapy.
Unlike continuous BTK inhibitor therapy, using a BTK inhibitor as part of a time-limited combination regimen does not appear to select for resistance mutations. This crucial distinction means that a BTK inhibitor could potentially be used again effectively as a subsequent line of therapy if the patient relapses.
CAR-T therapy involves a significant but finite period of acute toxicity (CRS, ICANS) that resolves within about a month. In contrast, bispecific antibodies can cause persistent, low-grade immune activation symptoms like fatigue and malaise that last for the entire duration of the continuous treatment.
Despite a major trial using rituximab in its pirtobrutinib-venetoclax combination, experts note a strong clinical preference for obinutuzumab as the more effective anti-CD20 antibody in CLL. This suggests that in real-world practice, clinicians may substitute obinutuzumab, adapting the trial regimen for perceived superior efficacy.
Clinical trial experience shows that delaying the administration of obinutuzumab in an Acalabrutinib-Venetoclax-Obinutuzumab (AVO) triplet regimen improves patient tolerability. This sequencing strategy allows clinicians to enhance response with the antibody later, if needed, while minimizing upfront side effects.
New oral BTK degraders show impressive response rates of 60-80% in CLL patients who have failed both covalent and non-covalent BTK inhibitors. However, the critical unknown is the durability of these responses. Future long-term data will determine their ultimate place in the treatment landscape.